PARTICIPANT INFORMATION AND AGREEMENT TO TAKE PART FORMParticipant Information and Agreement to Take Part Form • June 1st, 2021
Administrative information: Universal trial number: U1111-1201-6256 EudraCT number: 2017-003619-20 Version: 3.0 US Final Official name of the study:Long-term effects of semaglutide on diabetic retinopathy in patients with type 2 diabetes (FOCUS) Research sponsor contact information: Novo Nordisk A/S, Novo Allé, 2880 Bagsvaerd, Denmark A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required byU.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time. Information about the study and the results will also be made available at www.novonordisk- trials.com, www.clinicaltrialsregister.eu and potentially in other regional or local registries
Participant Information and Agreement to Take Part FormParticipant Information and Agreement to Take Part Form • June 15th, 2020
Does serial ultrasonography assessment for extravascular lung water and IVC measurement affect outcomes in inpatient heart failure management?
PARTICIPANT INFORMATION AND AGREEMENT TO TAKE PART FORMParticipant Information and Agreement to Take Part Form • April 12th, 2021
Universal trial number: U1111-1247-0210 EudraCT number: 2020-000299-39 Version: Final 3.0_US Official name of the study: Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in subjects with type 2 diabetes Research sponsor contact information: Novo Nordisk Inc, 800 Scudders Mill Road, Plainsboro, NJ 08536 A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required by U.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time. Information about the study and the results will also be made available at www.novonordisk-trials.com, www.clinicaltrialsregister.eu and potentially in other regional or local registries.
PARTICIPANT INFORMATION AND AGREEMENT TO TAKE PART FORMParticipant Information and Agreement to Take Part Form • December 24th, 2020
TITLE: A 78-week trial comparing the effect and safety of once weekly insulin icodec and once daily insulin glargine 100 units/mL, both in combination with non-insulin anti- diabetic treatment, in insulin naïve subjects with type 2 diabetes.
PARTICIPANT INFORMATION AND AGREEMENT TO TAKE PART FORMParticipant Information and Agreement to Take Part Form • October 7th, 2019
Administrative information: Universal trial number: U1111-1218-5368 EudraCT number/IND number: 2018-003141-42 Version: US_6.0 Official name of the study: Semaglutide cardiovascular outcomes trial in patients with type 2 diabetes (SOUL) Research sponsor contact information: Novo Nordisk A/S, Novo Allé, 2880 Bagsvaerd, Denmark A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required byU.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time. Information about the study and the results will also be made available at www.novonordisk- trials.com and www.clinicaltrialsregister.eu.
